Is now the right time to buy this ASX 200 stock? Here's my take

These shares are up 163% over the past year. Is it too late to add to your portfolio?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When an S&P/ASX 200 Index (ASX: XJO) stock has fallen or risen strongly, it is difficult to figure out whether it is a great time to buy.

That's because, psychologically, investors are likely to think that they have missed out on most of the profits of a stock that has already rocketed. 

Conversely, shares that have fallen are also intimidating because punters are fearful that there are more losses coming.

So what do you do?

One of the hottest ASX 200 stocks in recent times has been Neuren Pharmaceuticals Ltd (ASX: NEU).

The Neuren share price has soared an unbelievable 163% over the past 12 months.

Let's break down whether one should buy this ASX 200 stock, or avoid it like the plague:

A young girl looks up and balances a pencil on her nose, while thinking about a decision she has to make.

Image source: Getty Images

Professional investors aren't too worried

Firstly, it's worth noting that all five analysts surveyed on CMC Invest reckon Neuren is still a buy despite the massive run-up in price.

So they obviously think Neuren has plenty more upside to come.

The analysts at Elvest Fund, who are in this camp, thought last month's phase 2 clinical test results for NNZ-2591 "exceeded expectations" in its ability to combat Phelan-McDermid syndrome (PMS).

"The PMS results bode well for the Phase 2 trials of NNZ-2591 for Pitt Hopkins syndrome, Angelman syndrome and Prader-Willi syndrome, results of which will be released during CY24."

The team thought the results were even more convincing than the effectiveness of Daybue, which is a drug that Neuren already has on sale commercially.

"In the meantime, we expect to see continued strong sales growth for Daybue, which is licensed to NASDAQ-listed Acadia Pharmaceuticals Inc (NASDAQ: ACAD), who will next report in early February."

ASX 200 shares have no memory

Just this example shows that what has happened to the share price in the past has no bearing on what the future might hold.

When investors are fearful because of a steep increase or decrease in price in recent times, that is called "anchoring". And anchoring prevents rational decision-making.

The critical fact to remember is that stocks themselves have no memory. Their future direction has zero relationship to where they have been in the past.

Therefore there is no "right" or "wrong" time to buy a specific ASX 200 stock. 

If the business is going places and the metrics meet your investment criteria, then it's ripe for adding to the portfolio as a long-term holding.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Investing Strategies

A wad of $100 bills of Australian currency lies stashed in a bird's nest.
Dividend Investing

How many Rio Tinto shares do I need to buy for $10,000 a year in passive income?

Rio Tinto shares have a lengthy track record of paying two fully franked dividends a year.

Read more »

A group of people of all ages, size and colour line up against a brick wall using their devices.
Growth Shares

3 high-quality ASX 200 shares for beginners to buy and hold

For beginners, I would focus on quality businesses that can keep growing and become more valuable over time.

Read more »

A young man goes over his finances and investment portfolio at home.
Investing Strategies

My simple investing strategy if I had to start over

The new me would Invest regularly, reinvest dividends and ignore market volatility.

Read more »

long term and short term on white cubes
Growth Shares

2 top ASX shares to buy and hold for the next decade

These investments could generate significant returns.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Dividend Investing

I'd buy this ASX dividend stock in any market

I want passive income and this investment is a top option for it!

Read more »

A woman wearing green flexes her bicep.
Share Market News

These ASX dividend shares could power your retirement income

This mix delivers income, stability and long-term cash flow growth.

Read more »

Woman using a pen on a digital stock market chart in an office.
Blue Chip Shares

3 ASX 200 shares I'd buy and hold through any market cycle

Market cycles are impossible to avoid, so I would focus on businesses with strong positions and reasons to keep delivering…

Read more »

Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
Dividend Investing

CGT tax changes may encourage investors into ASX dividend shares: Expert

Yield may become more important to some investors than growth, says this expert.

Read more »